Belnacasan
As of the edition of 20 October 2026, Belnacasan is a small molecule: of no established status; acts on CASP1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Small molecule
- Registered trials
- 3, 0 stopped early
- Disease areas
- Infections; Lungs and airways; Nervous system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CASP1 | Caspase-1 | P29466 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 3 | 0 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Vertex | Lead sponsor of trials | 2004 to now |